While a US FDA advisory panel narrowly voted against approval of Trevena Inc.'s intravenous opioid Olinvo (oliceridine) on Oct. 11, several members indicated that the drug could get their support with more data.
The Anesthetic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval of the drug for acute pain in adults for whom an intravenous opioid is warranted
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?